Group at a Glance

A world-class developer and manufacturer of drug delivery solutions.

Who We Are

  • World-class developer and manufacturer of high volume disposable medical devices for drug delivery and point-of-care (POC) diagnostics
  • Significant product invention and development resources in R&D including a separate Innovation team in Cambridge
  • Bespak is a global market leader in the manufacture of inhaled drug delivery devices for Life Science partners
  • Benchmark capabilities in the manufacture of more than 500 million devices per annum in regulated markets
  • High barriers to entry: Intellectual Property, know-how, FDA regulatory approvals and economies of scale
  • Robust finances: profitable, cash generative, low gearing and high dividend payout

Our Strategy

  • Organic revenue growth from:
    • New developments in core respiratory business
    • Diversification into adjacent markets and territories
    • Increasing revenue by capturing more of the value chain
  • Investment in activities in adjacent/complementary technologies/markets
  • Operating leverage from growth, and ongoing cost efficiency

Key Products

  • Respiratory: metered dose inhaler valves, dry powder inhalers, integrated dose counters, actuators
  • Injectables: auto-injectors, needle-free injectors
  • Nasal: nasal drug delivery devices
  • Nicotine inhalation devices
  • Other: POC diagnostics devices
  • Other: medical check valves

Market Position

  • A global market leader in respiratory drug delivery
  • Growing franchise in injectables drug delivery
  • Over 500 million devices manufactured annually
  • In excess of nine major new programmes in development pipeline
  • Firm opportunities in attractive new growth market segments
  • Growing customer recognition as innovator on demand

Highlights of the Year

  • Continuing revenue, margin and profit growth with resilient core markets
  • Award of MHRA commercial drug handling licence in September 2013
  • Launch of Bespak's Syrina® auto-injector range and Lila® injector at the Parental Drug Association exhibition in Basel, Switzerland, in November 2013 to high, universal acclaim
  • Launch of Bespak's auto-safety injector (ASI) device in conjunction with Dr. Reddy's Laboratories (DRL)
  • Award of an exclusive multi-year commercial supply contract for DEV610 dry powder inhaler
  • Further capacity expansion for the Chiesi NEXThaler® dry powder inhaler launched in 2013
  • Further investment in Atlas Genetics alongside two leading global healthcare companies